Description: MyMD Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the development of drug products in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety, and sleep disorders. It commercializes MYMD-1, a novel therapeutic to impact conditions related to immunometabolic dysregulation; and SUPERA-1R, a synthetic cannabidiol that offers bioavailability and potency than botanicals. The company was incorporated in 2014 and is based in Tampa, Florida.
Home Page: www.mymd.com
MYMD Technical Analysis
855 North Wolfe Street
Baltimore,
MD
21205
United States
Phone:
856 848 8698
Officers
| Name | Title |
|---|---|
| Dr. Christopher C. Chapman Jr., M.D. | Pres, Chief Medical Officer & Director |
| Mr. Paul M. Rivard Esq. | Exec. VP of Operations & Gen. Counsel |
| Dr. Adam Kaplin M.D., Ph.D. | Chief Scientific Officer |
| Mr. Ian Rhodes CPA | Interim Chief Financial Officer |
| Ms. Katherine Whartenby Ph.D. | Chief Scientific Advisor & Member of Advisory Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0825 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-01-23 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |